The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Open accessAbstract
T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus. In an in vitro plaque reduction assay, T-705 showed potent inhibitory activity against influenza A, B, and C viruses, with 50% inhibitory concentrations (IC 50 s) of 0.013 to 0.48 μg/ml, while it showed no cytotoxicity at concentrations up to 1,000 μg/ml in Madin-Darby canine kidney cells. The selectivity index for influenza virus was more than 2,000. It was also active against a neuraminidase inhibitor-resistant virus and some amantadine-resistant viruses. T-705 showed weak activity against non-influenza virus RNA viruses, with the IC 50 s being higher for non-influenza virus RNA viruses than for influenza virus, and it had no activity against DNA viruses. Orally administered T-705 at 100 mg/kg of body weight/day (four times a day) for 5 days significantly reduced the mean pulmonary virus yields and the rate of mortality in mice infected with influenza virus A/PR/8/34 (3 × 10 2 PFU). These results suggest that T-705 may be a compound that is useful and highly selective against influenza virus infections and that has a mode of action different from those of commercially available drugs, such as amantadine, rimantadine, and neuraminidase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A. P., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. A., & Boyd, M. R. (1988) · PubMed · Cited by 2,342
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Influenza virus M2 protein has ion channel activity
Pinto, L. H., Holsinger, L. J., & Lamb, R. A. (1992) · Cell · doi:10.1016/0092-8674(92)90452-i · Cited by 1,213
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
Sidwell, R. W., Huffman, J. H., Khare, L., Allen, B., Witkowski, R., & Robins, K. (1972) · Science · doi:10.1126/science.177.4050.705 · Cited by 985
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y. N., Hong, Z., Andino, R., & Cameron, C. E. (2000) · Nature Medicine · doi:10.1038/82191 · Cited by 820
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762 · cited 1×
“Their therapeutic efficacies have been demonstrated in clinical studies (9, 19, 26).”
BackgroundA controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
Dolin, R., Reichman, R. C., Madore, H. P., Maynard, R., Linton, P. N., & Webber-Jones, J. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209023071002 · Cited by 501 · cited 1×
“Amantadine and rimantadine have similar levels of activity, but rimantadine is associated with significantly fewer adverse reactions (2).”
BackgroundIon channel activity of influenza A virus M2 protein: characterization of the amantadine block
Wang, C., Takeuchi, K., Pinto, L. H., & Lamb, R. A. (1993) · Journal of Virology · doi:10.1128/jvi.67.9.5585-5594.1993 · Cited by 494
Research works printed but not linked: 5
- Hui, M. B. V., E. J. Lien, and M. D. Trousdale. 1994. Inhibition of human adenoviruses by 1-(2′-hydroxy-5′-methoxybenzylidene)amino-3-hydroxyguanidine tosylate. Antivir. Res.24:261-273. · doi:10.1016/0166-3542(94)90074-4
- Kurokawa, M., H. Ochiai, K Nagasaka, M. Neki, H. Xu, S. Kadota, S. Sutardjo, T Matsumoto, T Namba, and K. Shiraki. 1993. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antivir. Res.22:175-188. · doi:10.1016/0166-3542(93)90094-y
- 10.1128/AAC.44.4.859-866.2000 · doi:10.1128/aac.44.4.859-866.2000
- U.S. Food and Drug Administration. 1986. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bull.16:7.
- Yukawa, T. A., M. Kurokawa, H. Sato, Y. Yoshida, S. Kageyama, T. Hasegawa, T. Namba, M. Imakita, T. Hozumi, and K. Shiraki. 1996. Prophylactic treatment of cytomegalovirus infection with traditional herbs. Antivir. Res.32:63-70. · doi:10.1016/0166-3542(95)00978-7
Cited by
Emergence and pandemic potential of swine-origin H1N1 influenza virus
Neumann, G., Noda, T., & Kawaoka, Y. (2009) · Nature · doi:10.1038/nature08157 · Cited by 1,561
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
Itoh, Y., Shinya, K., Kiso, M., Watanabe, T., Sakoda, Y., Hatta, M., Muramoto, Y., Tamura, D., Sakai-Tagawa, Y., Noda, T., et al. (2009) · Nature · doi:10.1038/nature08260 · Cited by 1,073
Self-citationFavipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Self-citationFavipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Self-citationChen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683296 · Cited by 849
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852
Antiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 622
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573
Self-citationCandidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
Mechanism of Action of T-705 against Influenza Virus
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.981-986.2005 · Cited by 546
Self-citationOestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D. F., Barnard, D. L., Gowen, B. B., Julander, J. G., & Morrey, J. D. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.02.198 · Cited by 471
Self-citationOmoto, S., Speranzini, V., Hashimoto, T., Noshi, T., Yamaguchi, H., Kawai, M., Kawaguchi, K., Uehara, T., Shishido, T., Naito, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27890-4 · Cited by 446
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting
Robson, F., Khan, K. S., Le, T. K., Paris, C., Demirbag, S., Barfuss, P., Rocchi, P., & Ng, W.-L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.027 · Cited by 396
Favipiravir: A new and emerging antiviral option in COVID-19
Agrawal, U., Raju, R., & Udwadia, Z. F. (2020) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2020.08.004 · Cited by 390
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
Noshi, T., Kitano, M., Taniguchi, K., Yamamoto, A., Omoto, S., Baba, K., Hashimoto, T., Ishida, K., Kushima, Y., Hattori, K., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.10.008 · Cited by 381
Shannon, A., Le, N. T.-T., Selisko, B., Eydoux, C., Alvarez, K., Guillemot, J.-C., Decroly, E., Peersen, O., Ferron, F., & Canard, B. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104793 · Cited by 352
Influenza virus resistance to neuraminidase inhibitors
Samson, M., Pizzorno, A., Abed, Y., & Boivin, G. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.014 · Cited by 343
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B., & Deval, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068347 · Cited by 268
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis
Hoffmann, H.-H., Kunz, A., Simon, V. A., Palese, P., & Shaw, M. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101143108 · Cited by 266
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90551-6 · Cited by 264
Human Influenza Virus Infections
Peteranderl, C., Schmoldt, C., & Herold, S. (2016) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0036-1584801 · Cited by 259
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Hayden, F. (2009) · Clinical Infectious Diseases · doi:10.1086/591851 · Cited by 256
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
Pandemic and seasonal influenza: therapeutic challenges
Memoli, M. J., Morens, D. M., & Taubenberger, J. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.03.024 · Cited by 51
Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies
Gowen, B. B., & Hickerson, B. T. (2017) · Journal of Microbiology · doi:10.1007/s12275-017-7029-8 · Cited by 26
“Favipiravir (T-705), a nucleoside analog first reported in 2002 as a potent inhibitor of influenza virus infections (Furuta et al., 2002), has surfaced as a promising broad-spectrum antiviral with proven high level antiviral activity against RVFV, CCHFV, SFTSV, and ANDV in rodent disease models…”
Metadata
- Authors
- Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., & Shiraki, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2002-04
- Volume
- 46
- Issue
- 4
- Pages
- 977-981
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2108367829
- Cited by
- 501
- References
- 25
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.